b The designation "PUC" has been assigned to The Upjohn Company by Plasmid Reference Center (Stan ford, CA, U.S.A.).
which acts on the hydroxyl group at the C-6 position of the actinamine moiety ( Fig. 1, lb) .7)
In this report we present data indicating that trospectomycin (la) is adenylylated by a cell-free extract of an E. coli strain which harbors a recombinant plasmid to direct overproduction of an adenylylating enzyme, and that the product of adenylylation is trospectomycin 6-(5'-adenylate) ( Fig. 1, 1 ).
Materials and Methods
Bacterial Strain E. coli strains used in this study are listed in Table 1 . The plasmid pUC18 (Fig. 2) , found in E. coli NR79, UC 3833, was transformed into E. coli MC1061, UC 9224, to generate E. coli UC 9464. Sub-cloning of Spectinomycin-resistance Gene Standard protocols were used for isolation of plasmids (pUC18, pBR322) from SDS lysates by ultracentrifugation and subsequent cloning of the spectinomycin-resistance gene of pUC18 into pBR322.8) Selection for spectinomycin-resistant clones was carried out employing antibiotic medium No. 3 (Difco) with 100 jug of spectinomycin per ml. The enzymesnecessary for molecular cloning were obtained from NewEngland Biolabs (Beverly, MA, U.S.A.).
Determination of Antibiotic Resistance
The MICwas determined by the established tube dilution method employing the 0.5
McFarland turbidity standard.^A , phage X digested by Hind III; B, PUCIS from strain UC 3833; C, pUC18 from strain UC 9464; D, pUC1153 from strain UC 12150; E, pBR322, (B-E, digested by BamU I).
Media
The modified mediumB of Nossal and Heppel10) was employed. For the MICdetermination, Muelter-Hinton broth (Difco) was used. THE JOURNAL OF ANTIBIOTICS OCT. 1988 Inactivation of Trospectomycin by Cell-free Extracts The cells (E. coli, UC 12150) were grown to late logarithmic phase in 100 ml of the medium described above. After washing twice in 20 ml of TS buffer (0.03 m NaCl, 0.01 m Tris, pH 7.0) the cells were resuspended in 60 ml of STE buffer (20% sucrose, 1 x 10"3 m EDTA, 3.3 x 10"2 m Tris, pH 7.1) and stirred at room temperature for 40 minutes. This was then centrifuged (13,000xg, 0°C, 10 minutes) to obtain a cell pellet, which was resuspended and stirred in 7.5 ml of ice cold distilled water for 25 minutes. Finally it was centrifuged (13,000 xg, 0°C, 20 minutes) to obtain clear supernatant (shockate), which represented a crude enzymepreparation. Protein in the shockate was quantitated by a Bio-Rad protein assay kit. For a larger scale inactivation of trospectomycin, a 4-liter culture was processed accordingly. Inactivation of trospectomycin was carried out (at 37°C, 1 1 hours) by mixing 125 jul of Tris-acetate buffer (0.5 m, pH 7.1), 75 [A of magnesium acetate (20 mM, pH 7.1), 50 ju\ of ATP (0.1 m), appropriate amount of the cell-free extract, trospectomycin (in water) and distilled water to make up a final volume of 500 fA.
Enzymatic Hydrolysis Seven jug of inactivated trospectomycin was treated with 136 jug of venom phosphodiesterase (Worthington Biochemical) and 70 jul of buffer solution consisting of 0.05 m glycine -NaOHbuffer (pH 9.0), 0.01 m MgCl2 and 0.05 m KC1in a total volume of 160 ju\. For a treatment with spleen phosphodiesterase (Worthington Biochemical) 300 jug of inactivated trospectomycin was mixed with 0.6 u of the enzyme and 100 /A of 0.25 m sodium succinate -HC1buffer (pH 6.5) in a total volume of 600 [A. In both cases the reaction mixtures were incubated at 37°C for 16 hours.
Spectroscopic Methods *H NMR spectra were recorded on a Varian XL-200 spectrometer operating at 100 MHz.Spectra were run in D2O using sodium 2,2-dimethyl-2-silapentane-5-sulfonate (SDSS) as internal reference. 13C NMR spectra were recorded on a Varian XL-200spectrometer operating at 50.3 MHz.D2O was used as the solvent. *H and 13C NMRchemical shifts are reported as ppm relative to TMS. IR spectra were obtained in mineral oil suspension on a Digilab Model 14D Fourier Transform Spectrometer. Fast atom bombardment (FAB) spectra were obtained on a VG-ZAB-2Fmass spectrometer.
Assay of Trospectomycin and Trospectomycin 6-(5/-Adenylate) lacks in vitro antibacterial activity, its formation from trospectomycin can be followed by measuring the loss of its antibacterial activity. To determine the amountof trospectomycin in reaction mixtures or preparations obtained during purification a standard assay using either E. coli UC51 or Bacillus subtilis UC 564 was employed. To assay for the presence of trospectomycin 6-(5'-adenylate), the phosphodiester bond was first hydrolyzed using snake venom phosphodiesterase by the procedure described above. The amount of trospectomycin in the hydrolysate was determined by a standard assay method.
TLC Analysis
The production and purification of trospectomycin 6-(5'-adenylate) were followed by TLCusing Silica gel GF plates (Analtech) and water as the mobile phase. UVabsorbing materials were detected by a short wavelength UVlamp. Bioinactive, UV-nonabsorbing materials were detected by permanganate-periodate spray reagent. Bioactive materials (trospectomycin) were detected by bioautography on agar seeded with E. coli UC51. Trospectomycin 6-(5/-adenylate) exhibited an Rf value of 0.4 in this TLC system.
Isolation and Purification of Trospectomycin 6-(5/-Adenylate) A reaction mixture containing approximately 500 mgof inactivated trospectomycin was adjusted to pH 7.5 and passed over a column containing 100 ml of Amberlite XAD-2(Rohm and Haas Co., Philadelphia, PA). The spent was collected as one fraction. The column was washed with 300 ml of water and eluted with . The reaction mixture and the fractions obtained during the chromatography were analyzed for bioactivity before and after treatment with snake venom phosphodiesterase by UVdetermination at 260 nm as well as by TLC. Results indicated that the starting material contained ATP, ADP, AMPand trospectomycin 6-(5/-adenylate) ; spent and aqueous wash contained mainly the different adenosine phosphates, while the methanolic eluates contained all of trospectomycin 6-(5/-adenylate) present in the reaction mixture. The methanolic eluates were combined and concentrated to an aqueous solution which was then freeze-dried to yield approximately 450mg of a colorless material; UV^max nm (a), 260 (18.5). TLC on this preparation showed the presence of trospectomycin 6-(5/-adenylate) and trace of adenosine phosphates (ATP, ADP, AMP). Isolation of Pure Trospectomycin 6-(5/-Adenylate) A column was prepared from 200 ml of Amberlite XAD-2in water. The starting material, 450 mg of the material isolated as described above, was dissolved in 20 ml of 0.1 m phosphate buffer (pH 7.0). This solution was passed over the column at a rate of 2ml per minute. The column was washed with 600ml of water, then with MeOH-water (10:90), 600ml; MeOH-water (30:70), 600ml; MeOH-water (50:50), 600ml; finally MeOH-water (70:30), 600ml. Fractions containing trospectomycin 6-(5'-adenylate) were combined, concentrated in an aqueous solution and freezedried to give 330 mg of pure trospectomycin 6-(5'-adenylate). is described in the following sections.
Results and Discussion
Subcloning a Spectinomycin-resistance Gene into pBR322 A spectinomycin adenylylating enzyme has previously been isolated from an E. coli strain NR73/ W677 which is phenotypically similar to the original parent strain (NR79/W677) used in this study.6) The initial examination revealed that the plasmid, pUC18, in NR79 exists as a low copy numbermolecule with molecular size of approximately 90 kb (Fig. 2) . In order to facilitate large scale adenylylation of trospectomycin by a cell-free extract of a spectinomycin-resistant strain of E. coli, we attempted to subclone the spectinomycin-resistance gene into a high copy number plasmid pBR322. We hoped that either a high copy number of the gene or a more efficient promoter on pBR322 would result in better production of the adenylylating enzyme. As outlined in Fig. 3 , the BamHI digested preparations of pUC18and pBR322 were ligated, and the mixture was transformed into E. coli MC1061. Amongthe spectinomycin-resistant transformants (selected on a plate containing 100 jug of spectinomycin per ml), the isolate UC 12150 harbored a plasmid (designated pUC1153, Figs. 2 and 3) consisting of pBR322 and a 4.7-kb insert. When the MICs of trospectomycin were compared among the E. coli strains (Table 2) , it was found that the newly constructed strain UC 12150 was much more resistant to the drug (MIC 1,280 /Wg/ml) than its isogenic parent UC9464, which harbors the original low copy plasmid pUC18(MIC 320 jug/ml). Similar differences in the spectinomycin MICswere observed among those strains (Table 2) .
Trospectomycin Inactivating Activity in the Osmotic Shockate of UC 12150 Cell-free extracts were prepared from osmotically shocked cells of UC9464 and the highly resistant strain UC12150 in order to determine their enzymatic activities to inactivate trospectomycin (Fig. 4) . For total inactivation of 50 //g oftrospectomycin in ll hours 20 /u\ (corresponding to osmotic shockate protein concentration of 108 jug/ml) of the high producer UC12150 shockate was required in a total volume of 500/A of the reaction mixture. On the other hand it took 50/A (corresponding to 210 jug/ml of the shockate protein) of the osmotic shockate prepared from the isogenic parent strain UC 9464 in order to inactivate 96% of the same amount of trospectomycin.
As indicated by the results in Table 4 . Reactivation of trospectomycin 6-(5'-adenylate). Atotal of 50 ix% of trospectomycin was treated by various amounts of the shockate preparations as described in Materials and Methods. Inactivation was measured on Bacillus subtilis UC564 as an assay organism. Table 3 , inactivation of trospectomycin requires ATP, MgCl2, and cell-free extract of E. coli UC12150. The inactivated trospectomycin was slowly reactivated by venomphosphodiesterase but not by spleen phosphodiesterase indicating linkage between 5'-P of ATP and trospectomycin (Table 4) .
Production and Isolation of Trospectomycin 6-(5/-Adenylate) A crude enzyme preparation was used to adenylylate 500 mgof trospectomycin as described in Materials and Methods. Since trospectomycin adenylate lacks in vitro antibacterial activity, its formation from trospectomycin was followed by measuring the loss of such antibacterial activity using E. coli UC 51 as the assay organism. Incubation of the reaction mixture for 15 hours (37°C) resulted in sufficient inactivation of trospectomycin and its transformation to a UV-absorbing material, which yielded trospectomycin upon treatment with snake venom phosphodiesterase. Isolation and purification of trospectomycin adenylate were followed by TLC, UVabsorption at 260 nmand in vitro assays before and after treatment with snake venom phosphodiesterase. Pure, "inactivated" trospectomycin was isolated from the reaction mixture by repeated chromatographies on Amberlite XAD-2as described in detail in the Materials and Methods. Trospectomycin adenylate was eluted with methanol -water (30 :70 to 50 : 50) and isolated as an amorphous colorless powder. TLCof this material showed the presence of only one compound.
Characterization and Structure of Trospectomycin Adenylate Trospectomycinadenylate was isolated as an amorphouscolorless material soluble in water and lower alcohols and practically insoluble in acetone as well as ethyl acetate. Analytical data combined with molecular weight determination by negative ion FAB-MS (Fig. 5 and Table 5 ) indicated the molecular formula of C27H42NO13PH2O; MW703 and 721 (hydrated form). The IR spectrum (Fig. 6) showed weak carbonyl absorption at 1738 cm"1 indicating the presence of some trospectomycin adenylate in the nonhydrated form. The UVspectrum showed a maximum at 258 nm (a=17.27, Zi=12,150) supporting the presence of an adenosine moiety in the molecule of inactivated trospectomycin. The molecular formula (specifically the presence of one P atom per molecule) and the conversion of trospectomycin adenylate to trospectomycin by treatment with snake venomphosphodiesterase (but not with spleen phosphodiesterase) indicated that inactivated trospectomycin has a structure in which trospectomycin is linked to the phosphate group of adenosine-5'-phosphate. This is in agreement with the potentiometric titration (KOH, 80% aq ethanol) results which showed the presence of an acidic group in trospectomycin adenylate. The assignment of the phosphate diester linkage at the C-6 position of the actinamine moiety of trospectomycin (Fig. 1) is based on comparison of 13C NMRspectra of trospectomycin and trospectomycin adenylate ( Fig. 7 and Table 5 ). As shown in Table 5 , there is an excellent agreement between the chemical shifts of 16 of the carbons of trospectomycin and the corresponding carbons of the adenylate.
The chemical shift of the remaining carbon (C-6) of trospectomycin appears at 3 64.9 while C-6 of trospectomycin adenylate has a chemical shift of 3 72.9. This is due to the deshielding effect of the phosphate group attached at C-6 of trospectomycin adenylate.n) Furthermore, the chemical shifts of the carbons of ribose and adenine moieties of trospectomycin adenylate are almost identical to those of adenosine 5'-phosphate (Table 5 ). It should be noted that the chemical shifts of C-5 of ribose in adenosine 5'-phosphate (3 64.4) and trospectomycin 6-(5'-adenylate) (3 65.3) are higher than the chemical shifts of C-5 of adenosine (3 61.9). This is also due to the deshielding effect of the phosphate group at C-5 of ribose.
We, therefore, conclude that 13C NMRalso indicates a phosphodiester bond* between C-6 of trospectomycin and C-5 of the ribose moiety of adenosine as shown in Fig. 1, 1 . The XH NMR spectrum (Fig. 7) indicates the presence of ll protons in the area of d 0.6 to 1.7 assigned to the CCH3and the four CH2 groups of trospectomycin 6-(5'-adenylate).
Absorptions (Fig. 8) is also in agreement with the conclusion that 1 (Fig. 1) is the structure of trospectomycin adenylate. Biological Properties of Trospectomycin 6-(5 /-Adenylate) Trospectomycin 6-(5'-adenylate) is bioinactive in vitro. In vitro treatment with venom phosphodiesterase slowly transforms the adenylate to trospectomycin which inhibits the growth of both Gram-positive (Table 4) and Gramnegative bacteria.12) When, however, trospectomycin 6-(5'-adenylate) was administered subcutaneously at 30 mg/kg, it did not protect mice infected with Streptococcus pyogenes indicating OCT. 1988 that in vivo enzymatic transformation of the ribonucleotide prodrug 1 (Fig. 1) to its active form la (Fig. 1) occurs slowly (if at all) . (The CD50 of trospectomycin in the same system was ca. 3.0 mg/kg.)
